Journal article
Interim report of a phase II clinical trial of bevacizumab (Bev) and low dose metronomic oral cyclophosphamide (mCTX) in recurrent ovarian (OC) and primary peritoneal carcinoma: A California Cancer Consortium Trial
Authors
Garcia AA; Oza AM; Hirte H; Fleming G; Tsao-Wei D; Roman L; Swenson S; Gandara D; Scudder S; Morgan R
Journal
Journal of Clinical Oncology, Vol. 23, No. 16_suppl, pp. 5000–5000
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
June 1, 2005
DOI
10.1200/jco.2005.23.16_suppl.5000
ISSN
0732-183X